Cara Therapeutics, Inc. (CARA)
15.96
-0.69 (-4.14%)
Inactive · Last trade price on Apr 15, 2025
Cara Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Cara Therapeutics stock have an average target of 12, which predicts a -24.81% decrease from the current stock price of 15.96.
Price Target: $12 (-24.81%)
Analyst Consensus: Hold
* Price targets were last updated on Jun 13, 2024.
Analyst Ratings
The average analyst rating for Cara Therapeutics stock from 3 stock analysts was "Hold". This means that analysts believed this stock was likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 4 | 4 | 4 | 4 | 4 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades $120 → $12 | Strong Buy → Hold | Downgrades | $120 → $12 | -24.81% | Jun 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jun 13, 2024 |
| Needham | Needham | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jun 13, 2024 |
| Needham | Needham | Strong Buy Reiterates $60 | Strong Buy | Reiterates | $60 | +275.94% | May 23, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $43 | Strong Buy | Reiterates | $43 | +170.68% | May 15, 2024 |
Financial Forecast
Revenue This Year
3.67M
from 7.14M
Decreased by -48.55%
Revenue Next Year
1.53M
from 3.67M
Decreased by -58.33%
EPS This Year
-0.79
from -15.53
EPS Next Year
-0.65
from -0.79
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 3.8M | 1.6M | 26.5M |
| Avg | 3.7M | 1.5M | 19.3M |
| Low | 3.5M | 1.5M | 12.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -47.0% | -57.1% | 1,629.2% |
| Avg | -48.5% | -58.3% | 1,163.2% |
| Low | -50.6% | -60.0% | 713.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.36 | -0.34 | -0.33 |
| Avg | -0.79 | -0.65 | -0.73 |
| Low | -1.11 | -1.10 | -1.10 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.